Basic and clinical studies on S-1108 in urinary tract infections

Noriaki Ono, Toyohiko Watanabe, Tadasu Takenaka, Toshihide Hayashi, Kazuhiro Hata, Hiromi Kumon, Hiroyuki Ohmori, Katsuiehi Nanba, Yoshikatsu Kondou, Teruhisa Ohhashi, Teruaki Akaeda

Research output: Contribution to journalArticlepeer-review


We studied the antibacterial activity and efficacy of S-1108, a new cephem antibiotic, in urinary tract infections. 1) Antibacterial activity : The MICs of S-1006 were measured against 202 clinical isolates of 14 species from urinary tract infections and compared with those of cefaclor (CCL), cefixime (CFIX) and cefteram (CFTM). In general, the antibacterial activity of S-1006 was almost equal to that of CFIX and CFTM, but superior to that of CCL. 2) Clinical efficacy : According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 84.2% (16/19) for chronic complicated UTI. Bacteriologically, 21 of the 22 strains isolated (95.4%) were eradicated. 3) Side effects : No clinical adverse reactions and no abnormal laboratory findings were observed.

Original languageEnglish
Pages (from-to)448-455
Number of pages8
Publication statusPublished - Jan 1 1993

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Basic and clinical studies on S-1108 in urinary tract infections'. Together they form a unique fingerprint.

Cite this